Drug details:
Molecular formula: C₂₅H₂₅Br₄N₁₃O₂

Standard name: N-[[1-[[(5R,6R)-2-amino-6-[[4-[[(4,5-dibromo-1H-pyrrole-2-carbonyl)amino]methyl]triazol-1-yl]methyl]-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methyl]triazol-4-yl]methyl]-4,5-dibromo-1H-pyrrole-2-carboxamide

Curated SMILES: NC1=NC2=C(C[C@@H](CN3C=C(CNC(=O)C4=CC(Br)=C(Br)N4)N=N3)[C@H](CN3C=C(CNC(=O)C4=CC(Br)=C(Br)N4)N=N3)C2)N1

Evidence for compound's anti-virulence activity:

Acinetobacter
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: Preclinical (in vitro)
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.

Staphylococcus
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: Preclinical (in vitro)
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.